Abstract: The present invention relates to a compound of formula (I) wherein n is 1 or 2, R1 is halogen, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, ethynyl, propargyl, or (C3-C6)cycloalkyl, or two R1 form a cyclopentane ring fused to the phenol; R2 and R3 represent H, cyano, ethynyl, propargyl, (C1-C4)alkyl, hydroxy(C1-C4)alkyl or a halo(C1-C4)alkyl, or R2 and R3 form together with the atoms connecting them a (C5- C6)carbocyclic ring fused to the pyridazine ring; R4 and R5 form together with N to which they are attached an optionally substituted 3-7 membered monocyclic heterocycloalkyl ring, 8-11 membered bicyclic heterocycloalkyl ring or 7-12 membered bicyclic heterocyclic spiro ring. The present invention also relates to a medicament and a pharmaceutical composition comprising said compound of formula (I), as well as their therapeutic uses, in particular as inhibitor of NOD-like receptor protein 3 inflammasome for treating for example Parkinson's disease or frontotemporal Dementia.
| # | Name | Date |
|---|---|---|
| 1 | 202517097948-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [10-10-2025(online)].pdf | 2025-10-10 |
| 2 | 202517097948-STATEMENT OF UNDERTAKING (FORM 3) [10-10-2025(online)].pdf | 2025-10-10 |
| 3 | 202517097948-REQUEST FOR EXAMINATION (FORM-18) [10-10-2025(online)].pdf | 2025-10-10 |
| 4 | 202517097948-FORM 18 [10-10-2025(online)].pdf | 2025-10-10 |
| 5 | 202517097948-FORM 1 [10-10-2025(online)].pdf | 2025-10-10 |
| 6 | 202517097948-DECLARATION OF INVENTORSHIP (FORM 5) [10-10-2025(online)].pdf | 2025-10-10 |
| 7 | 202517097948-COMPLETE SPECIFICATION [10-10-2025(online)].pdf | 2025-10-10 |
| 8 | 202517097948-FORM-26 [17-12-2025(online)].pdf | 2025-12-17 |